Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

ELIPSIS: developing tools to better understand VOC in SCD

Nirmish Shah

Blood (2021) 137 (15): 1987–1988.

https://doi.org/10.1182/blood.2020009466

Published: 2021

Journal Articles

A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)

Fuad A El Rassi, MD, Deepika S. Darbari, MD, Arthur Burnett, MD MBA, Jincy Paulose, MD, Dramane I Laine, Das Purkayastha, PhD, Gregory J Kato, MD

Blood (2019) 134 (Supplement_1): 1007.

https://doi.org/10.1182/blood-2019-125790

Published: 2019

Journal Articles

Patient-Reported Outcome Measures (PROMs) in Pediatric Non-Malignant Hematology: A Systematic Review

Robert J Klaassen, MD FRCPC, Julia Y. Kinahan, MDcal Student, Johann M. I. Graham, MDcal Student, Yamilée V. Hébert, MDcal Student, Katie O'Hearn, MSc Human Kinetics

Blood (2019) 134 (Supplement_1): 2180.

https://doi.org/10.1182/blood-2019-127248

Published: 2019

Journal Articles

Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study

Mariasanta Napolitano, Simona Raso, MD, Maria Francesca Mansueto, PhD, Salvatrice Mancuso, MD, Matteo Nicola Dario Di Minno, MD PhD, Dalila Scaturro, MD, Giulia Letizia Mauro, Prof,MD, Giovanni Di Minno, Sergio Siragusa, Prof, MD

Blood (2019) 134 (Supplement_1): 3455.

https://doi.org/10.1182/blood-2019-128129

Published: 2019

Journal Articles

Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia

Blood (2019) 134 (Supplement_1): 615.

https://doi.org/10.1182/blood-2019-123355

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Stage I, II or III Mycosis Fungoides (MF)

Malgorzata Sokołowska-Wojdyło, MD, Izabela Blazewicz, PhD, Berenika Olszweska, PhD, Ewa Maria Zak, MSc, Walter Klemp, Sandra L Silberman, MD PhD, Waldemar Priebe, PhD

Blood (2019) 134 (Supplement_1): 5272.

https://doi.org/10.1182/blood-2019-125118

Published: 2019

Journal Articles

Content Validation of Sickle Cell Pain Diaries for Caregivers: Results from Interviews with Caregivers

Miranda Bailey, Patricia Stebbins, MPPM, Denise D'Alessio, MBA, April Mitchell, BSc, Cory Saucier, MPH, Michelle K White, PhD

Blood (2018) 132 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2018-99-119410

Published: 2018

Journal Articles

Straightforward Transition to Bay 81-8973 Prophylaxis in Patients with Hemophilia A: Prospective Real-World Data from the Taurus Non-Interventional Study Show That Number of Infusions per Week Is Maintained or Reduced

Michael Wang, Beng Fuh, MD, Philip Maes, MD, Maria Eva Mingot-Castellano, PhD MD, Rubén Berrueco, MD, Phu-Quoc Le, MD PhD, Stephan Rauchensteiner, Cristina Santoro, MD PhD

Blood (2018) 132 (Supplement 1): 5045.

https://doi.org/10.1182/blood-2018-99-116622

Published: 2018

Journal Articles

Defining Sickle Cell Disease Acute Painful Episodes: The Pisces Project

Donna k McClish, PhD, Wally R. Smith, MD, Joshua J. Field, MD, Samir K. Ballas, MD, Claudia M Campbell, PhD, Lori E. Crosby, PhD, Carlton Dampier, MD, Deepika S. Darbari, MD, William Zempsky, MD

Blood (2018) 132 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2018-99-114830

Published: 2018

Journal Articles

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Mark T. Reding, MD, Shadan Lalezari, Dr, Ingrid Pabinger, MD, Monica Maas Enriquez, Dr, Jonathan M. Ducore, MD

Blood (2018) 132 (Supplement 1): 1206.

https://doi.org/10.1182/blood-2018-99-116272

Published: 2018

Journal Articles

Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Prospective Non-Interventional Study with Netupitant/Palonosetron Fixed Dose Combination (NEPA)

Meinolf Karthaus, P Klare, N Gazawi, MO Zahn, B Reimann, S Busch, Joerg Schilling

Blood (2018) 132 (Supplement 1): 4844.

https://doi.org/10.1182/blood-2018-99-113489

Published: 2018

Journal Articles

Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers

Blood (2018) 132 (Supplement 1): 2258.

https://doi.org/10.1182/blood-2018-99-120049

Published: 2018

Journal Articles

Defining Vaso-Occlusive Crises in Sickle Cell Disease from the Perspective of the Patient: Development of a New Toolbox to Measure Treatment Outcomes

Andreas M Pleil, PhD, Alexandra Barsdorf, PhD, Michael U. Callaghan, Karin Coyne, PhD, Katy Benjamin, PhD, David Beidler, PhD, Robert J Charnigo, MS

Blood (2017) 130 (Supplement 1): 3415.

https://doi.org/10.1182/blood.V130.Suppl_1.3415.3415

Published: 2017

Journal Articles

Quality of Life and Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Meinolf Karthaus, MD, P Klare, V Heilmann, G Klausmann, Joerg Schilling

Blood (2017) 130 (Supplement 1): 2180.

https://doi.org/10.1182/blood.V130.Suppl_1.2180.2180

Published: 2017

Journal Articles

Comparing Medication Adherence Tools for the Direct Oral Anticoagulants Rivaroxaban and Apixaban

Lana A Castellucci, MD, Philip Chiang, Amanda Pecarskie, Gregoire Le Gal, Marc Rodger, MD FRCPC

Blood (2017) 130 (Supplement 1): 3713.

https://doi.org/10.1182/blood.V130.Suppl_1.3713.3713

Published: 2017

Journal Articles

Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia a or B with Inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-Interventional SMART-7 ™ Study

Gary Benson, Hervé Chambost, Francesco Demartis, Soraya Benchikh El Fegoun, Katarina Cepo, Lene Sommer, Kaan Kavakli

Blood (2016) 128 (22): 1439.

https://doi.org/10.1182/blood.V128.22.1439.1439

Published: 2016

Journal Articles

Mobile Application Vs. Paper Pictorial Blood Assessment Chart to Track Menses in Young Women: A Randomized Cross-over Design

Amanda E. Jacobson, MD, Sara K. Vesely, PhD, Myra Christian-Rancy, Sarah H. O'Brien, MD MSc

Blood (2016) 128 (22): 1006.

https://doi.org/10.1182/blood.V128.22.1006.1006

Published: 2016

Journal Articles

N-Acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled Trial

Blood (2016) 128 (22): 123.

https://doi.org/10.1182/blood.V128.22.123.123

Published: 2016

Journal Articles

Regional- and Age-Related Differences in Pain in Children with Sickle Cell Anemia: Results from the Multinational DOVE Study

Julie Kanter, MD, Lori E Heath, MS, Chunmei Zhou, MS, Tsiri Agbenyega, MBChB, PhD, Raffaella Colombatti, MD PhD, Carlton Dampier, MD CPI, Hoda M Hassab, MD, Deepa Manwani, MD, Nancy Robitaille, MD, Patricia B Brown, BSN, RN, Joseph A. Jakubowski, PhD, Suqin Yao, PhD, Jack Knorr, PhD, Carolyn C Hoppe, MD

Blood (2016) 128 (22): 3654.

https://doi.org/10.1182/blood.V128.22.3654.3654

Published: 2016

Journal Articles

Chemotherapy-Induced Nausea and Vomiting (CINV) - First Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Meinolf Karthaus, P Klare, V Heilmann, G Klausmann, Joerg Schilling

Blood (2016) 128 (22): 3614.

https://doi.org/10.1182/blood.V128.22.3614.3614

Published: 2016

NARROW

ELIPSIS: developing tools to better understand VOC in SCD

A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)

Patient-Reported Outcome Measures (PROMs) in Pediatric Non-Malignant Hematology: A Systematic Review

Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study

Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia

A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Stage I, II or III Mycosis Fungoides (MF)

Content Validation of Sickle Cell Pain Diaries for Caregivers: Results from Interviews with Caregivers

Straightforward Transition to Bay 81-8973 Prophylaxis in Patients with Hemophilia A: Prospective Real-World Data from the Taurus Non-Interventional Study Show That Number of Infusions per Week Is Maintained or Reduced

Defining Sickle Cell Disease Acute Painful Episodes: The Pisces Project

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Prospective Non-Interventional Study with Netupitant/Palonosetron Fixed Dose Combination (NEPA)

Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers

Defining Vaso-Occlusive Crises in Sickle Cell Disease from the Perspective of the Patient: Development of a New Toolbox to Measure Treatment Outcomes

Quality of Life and Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Comparing Medication Adherence Tools for the Direct Oral Anticoagulants Rivaroxaban and Apixaban

Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia a or B with Inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-Interventional SMART-7 ™ Study

Mobile Application Vs. Paper Pictorial Blood Assessment Chart to Track Menses in Young Women: A Randomized Cross-over Design

N-Acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled Trial

Regional- and Age-Related Differences in Pain in Children with Sickle Cell Anemia: Results from the Multinational DOVE Study

Chemotherapy-Induced Nausea and Vomiting (CINV) - First Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only